Edition:
United States

Medivation Inc (MDVN.OQ)

MDVN.OQ on NASDAQ Stock Exchange Global Select Market

62.63USD
22 Jul 2016
Change (% chg)

$0.09 (+0.14%)
Prev Close
$62.54
Open
$62.79
Day's High
$63.25
Day's Low
$62.50
Volume
154,536
Avg. Vol
905,244
52-wk High
$63.25
52-wk Low
$26.48

MDVN.OQ

Chart for MDVN.OQ

About

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $10,310.45
Shares Outstanding(Mil.): 164.62
Dividend: --
Yield (%): --

Financials

  MDVN.OQ Industry Sector
P/E (TTM): 43.81 39.80 37.05
EPS (TTM): 1.43 -- --
ROI: 25.02 -5.86 14.35
ROE: 36.85 -4.70 15.56

Medivation agrees to open its books to Sanofi

U.S. cancer drug company Medivation Inc said on Tuesday it had agreed to provide confidential information to French pharmaceutical company Sanofi SA as part of exploring a sale that would be open to other bidders. | Video

Jul 06 2016

BRIEF-Sanofi raises Medivation offer, enters confidentiality agreement

* Sanofi confirms it has entered into a confidentiality agreement with Medivation under which it will be provided due diligence access and confidential information.

Jul 05 2016

BRIEF-Sanofi sounding out Medivation shareholders as it prepares to raise bid- CNBC

* Sanofi sounding out Medivation shareholders as it prepares to raise bid- CNBC (Bengaluru Newsroom: +1 646 223 8780)

Jun 28 2016

Medical device maker Medtronic to buy HeartWare for $1.1 billion

Medtronic Plc said it would buy HeartWare International Inc for about $1.1 billion, bulking up its portfolio of devices for treating heart diseases and pushing deeper into the market for less-invasive surgical products.

Jun 27 2016

UPDATE 2-Medical device maker Medtronic to buy HeartWare for $1.1 bln

* Deal expected to close by October end (Adds details; updates shares)

Jun 27 2016

Glass Lewis urges Medivation shareholders to support current board

Medivation Inc said shareholder advisory firm Glass Lewis & Co has recommended the cancer drug maker's stockholders to not support Sanofi SA's efforts to replace the company's board members.

Jun 24 2016

Glass Lewis urges Medivation shareholders to support current board

June 24 Medivation Inc said shareholder advisory firm Glass Lewis & Co has recommended the cancer drug maker's stockholders to not support Sanofi SA's efforts to replace the company's board members.

Jun 24 2016

BRIEF-Sanofi announces expiration of Hart-Scott-Rodino waiting period for proposed acquisition of Medivation

* Sanofi announces expiration of hart-scott-rodino waiting period regarding proposed acquisition of medivation Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 14 2016

CORRECTED-UPDATE 1-Sanofi, Medivation advance to next phase of takeover fight

NEW YORK, June 13 French drugmaker Sanofi and its takeover target Medivation Inc on Monday said they had filed official materials with the U.S. Securities and Exchange Commission, as their $9.3 billion battle advances to the next phase.

Jun 13 2016

Sanofi files request to replace Medivation board

PARIS French drugmaker Sanofi said on Monday that it had filed a request with U.S. authorities to remove the board of Medivation and replace it with eight independent candidates as it seeks to acquire the cancer drug company.

Jun 13 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.03 -0.12
Sanofi SA (SASY.PA) €76.60 --
Bayer AG (BAYGn.DE) €92.07 --
Bayer AG (BAYE.F) -- --
Orion Corp (001800.KS) ₩937,000.00 +7,000.00
TOKAI Corp. (9729.T) ¥3,325 +55.00
Bristol-Myers Squibb Co (BMY.N) $75.68 +0.18
Bristol-Myers Squibb Co (BMYMP.PK) $1,231.90 --
Roche Holding Ltd. (ROG.S) CHF249.80 --
Roche Holding Ltd. (RO.S) CHF252.25 --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.